FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2757963532> ?p ?o ?g. }

• W2757963532 abstract "This review is the first update of a previously published review in The Cochrane Library (Issue 7, 2015). Interleukin-5 (IL-5) is the main cytokine involved in the activation of eosinophils, which cause airway inflammation and are a classic feature of asthma. Monoclonal antibodies targeting IL-5 or its receptor (IL-5R) have been developed, with recent studies suggesting that they reduce asthma exacerbations, improve health-related quality of life (HRQoL) and lung function. These are being incorporated into asthma guidelines.To compare the effects of therapies targeting IL-5 signalling (anti-IL-5 or anti-IL-5Rα) with placebo on exacerbations, health-related qualify of life (HRQoL) measures, and lung function in adults and children with chronic asthma, and specifically in those with eosinophilic asthma refractory to existing treatments.We searched the Cochrane Airways Trials Register, clinical trials registries, manufacturers' websites, and reference lists of included studies. The most recent search was March 2017.We included randomised controlled trials comparing mepolizumab, reslizumab and benralizumab versus placebo in adults and children with asthma.Two authors independently extracted data and analysed outcomes using a random-effects model. We used standard methods expected by Cochrane.Thirteen studies on 6000 participants met the inclusion criteria. Four used mepolizumab, four used reslizumab, and five used benralizumab. One study in benralizumab was terminated early due to sponsor decision and contributed no data. The studies were predominantly on people with severe eosinophilic asthma, which was similarly but variably defined. Eight included children over 12 years but these results were not reported separately. We deemed the risk of bias to be low, with all studies contributing data being of robust methodology. We considered the quality of the evidence for all comparisons to be high overall using the GRADE scheme, with the exception of intravenous mepolizumab because this is not currently a licensed delivery route.All of the anti-IL-5 treatments assessed reduced rates of 'clinically significant' asthma exacerbation (defined by treatment with systemic corticosteroids for three days or more) by approximately half in participants with severe eosinophilic asthma on standard of care (at least medium-dose inhaled corticosteroids (ICS)) with poorly controlled disease (either two or more exacerbations in the preceding year or Asthma Control Questionnaire (ACQ) 1.5 or more). Non-eosinophilic participants treated with benralizumab also showed a significant reduction in exacerbation rates, but no data were available for non-eosinophilic participants, and mepolizumab or reslizumab.We saw modest improvements in validated HRQoL scores with all anti-IL-5 agents in severe eosinophilic asthma. However these did not exceed the minimum clinically important difference for ACQ and Asthma Quality of Life Questionnaire (AQLQ), with St. George's Respiratory Questionnaire (SGRQ) only assessed in two studies. The improvement in HRQoL scores in non-eosinophilic participants treated with benralizumab, the only intervention for which data were available in this subset, was not statistically significant, but the test for subgroup difference was negative.All anti-IL-5 treatments produced a small but statistically significant improvement in mean pre-bronchodilator forced expiratory flow in one second (FEV1) of between 0.08 L and 0.11 L.There were no excess serious adverse events with any anti-IL-5 treatment, and indeed a reduction in favour of mepolizumab that could be due to a beneficial effect on asthma-related serious adverse events. There was no difference compared to placebo in adverse events leading to discontinuation with mepolizumab or reslizumab, but significantly more discontinued benralizumab than placebo, although the absolute numbers were small (36/1599 benralizumab versus 9/998 placebo).Mepolizumab, reslizumab and benralizumab all markedly reduced blood eosinophils, but benralizumab resulted in almost complete depletion, whereas a small number remained with mepolizumab and reslizumab. The implications for efficacy and/or adverse events are unclear.Overall our study supports the use of anti-IL-5 treatments as an adjunct to standard of care in people with severe eosinophilic asthma and poor control. These treatments roughly halve the rate of asthma exacerbations in this population. There is limited evidence for improved HRQoL scores and lung function, which may not meet clinically detectable levels. There were no safety concerns regarding mepolizumab or reslizumab, and no excess serious adverse events with benralizumab, although there remains a question over adverse events significant enough to prompt discontinuation.Further research is needed on biomarkers for assessing treatment response, optimal duration and long-term effects of treatment, risk of relapse on withdrawal, non-eosinophilic patients, children (particularly under 12 years), and comparing anti-IL-5 treatments to each other and, in people eligible for both, to anti-immunoglobulin E. For benralizumab, future studies should closely monitor rates of adverse events prompting discontinuation." @default.
• W2757963532 created "2017-10-06" @default.
• W2757963532 creator A5014842174 @default.
• W2757963532 creator A5023731735 @default.
• W2757963532 creator A5029606237 @default.
• W2757963532 creator A5037509074 @default.
• W2757963532 creator A5058933163 @default.
• W2757963532 date "2017-09-21" @default.
• W2757963532 modified "2023-10-16" @default.
• W2757963532 title "Anti-IL5 therapies for asthma" @default.
• W2757963532 cites W151192511 @default.
• W2757963532 cites W1549472286 @default.
• W2757963532 cites W1621135942 @default.
• W2757963532 cites W1869441945 @default.
• W2757963532 cites W1916962812 @default.
• W2757963532 cites W1947099084 @default.
• W2757963532 cites W1949221250 @default.
• W2757963532 cites W1966794651 @default.
• W2757963532 cites W1967215794 @default.
• W2757963532 cites W1967523833 @default.
• W2757963532 cites W1970648068 @default.
• W2757963532 cites W1971248629 @default.
• W2757963532 cites W1971325026 @default.
• W2757963532 cites W1972371950 @default.
• W2757963532 cites W1972386849 @default.
• W2757963532 cites W1973012417 @default.
• W2757963532 cites W1974526921 @default.
• W2757963532 cites W1976065152 @default.
• W2757963532 cites W1977801998 @default.
• W2757963532 cites W1978195578 @default.
• W2757963532 cites W1980505425 @default.
• W2757963532 cites W1983832849 @default.
• W2757963532 cites W1984973837 @default.
• W2757963532 cites W1986583097 @default.
• W2757963532 cites W1987444459 @default.
• W2757963532 cites W1988614216 @default.
• W2757963532 cites W1988758075 @default.
• W2757963532 cites W1990451108 @default.
• W2757963532 cites W1990470211 @default.
• W2757963532 cites W1994585625 @default.
• W2757963532 cites W2000650705 @default.
• W2757963532 cites W2002292213 @default.
• W2757963532 cites W2003860540 @default.
• W2757963532 cites W2006153464 @default.
• W2757963532 cites W2012810413 @default.
• W2757963532 cites W2013105339 @default.
• W2757963532 cites W2014574895 @default.
• W2757963532 cites W2015385334 @default.
• W2757963532 cites W2016058269 @default.
• W2757963532 cites W2017312401 @default.
• W2757963532 cites W2020989669 @default.
• W2757963532 cites W2021701428 @default.
• W2757963532 cites W2022877219 @default.
• W2757963532 cites W2024099103 @default.
• W2757963532 cites W2024286006 @default.
• W2757963532 cites W2025111901 @default.
• W2757963532 cites W2027018720 @default.
• W2757963532 cites W2027819154 @default.
• W2757963532 cites W2028065290 @default.
• W2757963532 cites W2029587541 @default.
• W2757963532 cites W2031029516 @default.
• W2757963532 cites W2031161541 @default.
• W2757963532 cites W2033228689 @default.
• W2757963532 cites W2033975621 @default.
• W2757963532 cites W2035551749 @default.
• W2757963532 cites W2039164436 @default.
• W2757963532 cites W2039930386 @default.
• W2757963532 cites W2041651163 @default.
• W2757963532 cites W2044067055 @default.
• W2757963532 cites W2046135796 @default.
• W2757963532 cites W2046313062 @default.
• W2757963532 cites W2048725737 @default.
• W2757963532 cites W2050684618 @default.
• W2757963532 cites W2050708037 @default.
• W2757963532 cites W2052977441 @default.
• W2757963532 cites W2055111979 @default.
• W2757963532 cites W2055172715 @default.
• W2757963532 cites W2055220989 @default.
• W2757963532 cites W2057490898 @default.
• W2757963532 cites W2061775758 @default.
• W2757963532 cites W2062574496 @default.
• W2757963532 cites W2062918919 @default.
• W2757963532 cites W2064248794 @default.
• W2757963532 cites W2065071227 @default.
• W2757963532 cites W2065797637 @default.
• W2757963532 cites W2067360235 @default.
• W2757963532 cites W2067743660 @default.
• W2757963532 cites W2068049003 @default.
• W2757963532 cites W2068966334 @default.
• W2757963532 cites W2071678055 @default.
• W2757963532 cites W2073648701 @default.
• W2757963532 cites W2073959308 @default.
• W2757963532 cites W2075699130 @default.
• W2757963532 cites W2075763559 @default.
• W2757963532 cites W2076114528 @default.
• W2757963532 cites W2077618744 @default.
• W2757963532 cites W2084370208 @default.
• W2757963532 cites W2084607526 @default.
• W2757963532 cites W2086373045 @default.
• W2757963532 cites W2092153325 @default.

• next